

ASX ANNOUNCEMENT

13 December 2024

Confirmation of implementation timetable

Anteris Technologies Ltd (ASX: AVR) (**ATL** or the **Company**) is pleased to announce that, further to its earlier announcement confirming the pricing of the Holdco (Anteris Technologies Global Corp. (ATGC)) IPO, the Condition Subsequent to the Schemes has been satisfied.

ATL confirms the following timetable for implementation of the Schemes.

Event	Date
Holdco Shares commence trading on Nasdaq	Friday 13 December 2024 (US time)
Implementation Date of the Schemes	Monday 16 December 2024 (Australia time)
Completion of Holdco IPO	Monday 16 December 2024 (US time)
Commencement of trading of Holdco CDIs on a Normal Settlement Basis	Tuesday 17 December 2024 (Australia time)
Commencement of trading of Holdco shares issued under the Share Scheme on Nasdaq	Tuesday 17 December 2024 (US time)
Dispatch of Holdco CDI statements	Wednesday 18 December 2024 (Australia time)
Dispatch of Holdco Share statements	Wednesday 18 December 2024 (US time)

All capitalised terms used in this announcement have the meaning given in the Scheme Booklet dated 2 September 2024 as supplemented by the Supplementary Scheme Booklet dated 12 November 2024.

This announcement is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation or sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. As disclosed in the registration statement, the underwriters may engage in stabilizing actions or related activities in connection with the Holdco IPO.

ENDS



About ATGC

ATGC was incorporated on January 29, 2024 for the purpose of reorganizing the operations of Anteris Technologies Ltd (**Anteris**), an Australian public company originally registered in Western Australia, Australia and listed on the ASX, into a structure whereby the ultimate parent company will be a Delaware corporation.

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercializing innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering potentially transformative solutions to structural heart disease patients.

Anteris' lead product, DurAVR[®], is a transcatheter heart valve for treating aortic stenosis. It is the first transcatheter aortic valve replacement to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR[®] THV is made using ADAPT[®] tissue, Anteris' patented anti-calcification tissue technology. ADAPT[®] tissue has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.

The ComASUR[®] Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR[®] THV with balloon-expandable delivery, designed to achieve precise alignment with the heart's native commissures to achieve ideal valve positioning.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Investor Relations

investors@anteristech.com
Anteris Technologies Ltd
+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

Malini Chatterjee, Ph.D.
Managing Director
Blueprint Life Science Group
+1 917 330 4269

Website	www.anteristech.com
X	@AnterisTech
Facebook	www.facebook.com/AnterisTechnologies
LinkedIn	https://www.linkedin.com/company/anteristech

